LONDON – Summer has been slow to arrive in Europe this year, something that is maybe a blessing for patients with erythropoietic protoporphyria (EPP), an extreme sensitivity to sunlight, who have been awaiting the market rollout of the first approved treatment, Scenesse (afamelanotide).